Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis (Q33522848)

27 July 2017

0 references

1 reference

title

Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis (English)

1 reference

27 July 2017

0 references

1 reference

Antonis Valachis

1

1 reference

27 July 2017

Nikolaos P Polyzos

2

1 reference

27 July 2017

Vassilis Georgoulias

3

1 reference

27 July 2017

Dimitris Mavroudis

4

1 reference

27 July 2017

Davide Mauri

5

1 reference

27 July 2017

language of work or name

English

0 references

publication date

12 January 2010

1 reference

27 July 2017

1 reference

27 July 2017

volume

117

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

139-145

1 reference

Osteoporosis due to cancer treatment: pathogenesis and management

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Bone loss induced by cancer treatment and its management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Quantitative synthesis in systematic reviews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Predictive Value of BMD for Hip and Other Fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.12.001

10.1016/J.YGYNO.2009.12.001

7 January 2021

Identifiers

DOI

1 reference

release_qvj767meq5e5xjyke5pdc7vshi

27 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qvj767meq5e5xjyke5pdc7vshi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference